Alveus, Lilly, Viking and Amgen are testing maintenance strategies as durability becomes a bigger focus in obesity R&D.

The pharma and biotech industries are constantly in flux. Every year, pharma professionals converge on a number of large ...

Dr. John Tsai grabbed the reins of global R&D this year with a clear mandate: extend Daiichi’s oncology momentum beyond its ...

Progress often happens in slow trickles. And in the movement toward LGBTQ+ equality, small political advances over decades have led to a larger cultural shift. In just the last 10 years, same-sex ...

The Danish biotech sharpened its global vaccine ambitions by tapping Tarja Stenvall, a Big Pharma vet, to take the helm.

The error points to a big question for pharma as AI gains autonomy and high-profile failures sharpen safety concerns: What ...

Nimbus Therapeutics’ head of R&D dishes on what’s next in AI-enabled drug discovery, years after Takeda completed its ...

Basecamp Research just netted $140 million in a series C fundraising round that valued the company at $800 million, according ...

Drugs targeting the GLP-1 receptor and PD-1/PD-L1 pathway are money spinners for companies like Eli Lilly, Novo Nordisk and Merck and Co., so it’s no surprise that drug developers continue to chase ...

Roche announced it's building autonomous AI-powered labs; how a clinical hold on an epilepsy trial could impact Biohaven ...

It’s easy to understand why more than 90% of patients in psychedelic trials know they received the study drug. Even when trials use a drug in the comparison group that produces a noticeable effect, ...